Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Migration and transformation of organic carbon and nutrients in rice straw during hydrothermal cracking.

Waste management (New York, N.Y.)·2026
Same author

Agomelatine for Sjögren's syndrome: a study on its therapeutic effects and mechanisms.

Inflammopharmacology·2026
Same author

Inhibitors of the Machupo Virus L Endonuclease for Bolivian Hemorrhagic Fever Treatments.

Microorganisms·2026
Same author

Investigating the impact of collateral circulation pathways on hemodynamics in iliac vein compression syndrome.

Frontiers in bioengineering and biotechnology·2026
Same author

pH-responsive in situ hydrogelation behavior of a dipotassium glycyrrhizinate-propylene glycol alginate micro-hydrogel for oral sustained release of kaempferol.

Colloids and surfaces. B, Biointerfaces·2026
Same author

Melatonin-Mediated Modulation of Polyamines Enhances Drought Tolerance in Foxtail Millet (Setaria italica L.).

Journal of pineal research·2026

Related Experiment Video

Updated: Jun 30, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.5K

Type I Interferon Signaling Augments Autoimmunity in Neuromyelitis Optica Spectrum Disorder.

Tian-Xiang Zhang1, Xiaoxiao Yang2, Xue Gao1

  • 1Department of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|July 21, 2025
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica spectrum disorder (NMOSD) involves abnormal immune cell signaling. Inhibiting the cGAS-STING-IFN-I pathway reduces autoimmune responses and disease severity in NMOSD models.

Keywords:
T cellsinnate immune responseneuromyelitis optica spectrum disordertype I interferon

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K

Related Experiment Videos

Last Updated: Jun 30, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.5K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K

Area of Science:

  • Neuroimmunology
  • Autoimmune Disorders
  • Cellular Signaling

Background:

  • Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy targeting aquaporin 4 (AQP4) with unknown mechanisms for interferon-beta (IFN-β) treatment failure.
  • Myeloid cells in NMOSD exhibit robust activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING)-interferon type I (IFN-I) signaling pathway.

Purpose of the Study:

  • To investigate the role of the cGAS-STING-IFN-I pathway in NMOSD pathogenesis.
  • To explore the therapeutic potential of targeting this pathway for NMOSD treatment.

Main Methods:

  • Analysis of cGAS-STING-IFN-I pathway activation in myeloid cells from NMOSD patients and mouse models.
  • Assessment of AQP4-specific T cell responses and astrocyte damage in STING-deficient mice.
  • Evaluation of STING inhibitor H151 efficacy in NMOSD mouse models.

Main Results:

  • The cGAS-STING-IFN-I pathway is robustly activated in myeloid cells in NMOSD, driving an increase in AQP4-specific autoreactive T cells.
  • STING deficiency significantly reduces T cell activation, IFN-I activity in microglia, and astrocyte damage, ameliorating NMOSD clinical manifestations in a mouse model.
  • STING inhibitor H151 treatment alleviates NMOSD severity in mouse models.

Conclusions:

  • The cGAS-STING-IFN-I pathway plays a critical role in promoting autoreactive T cells in NMOSD.
  • Inhibiting the cGAS-STING-IFN-I pathway represents a promising novel therapeutic strategy for NMOSD.